Erectile dysfunction and cardiovascular disease

Postgraduate Medicine

Volumn 124, Issue 1, 2012, Pages 7-16

  Menezes, Arthur ^a   Artham, Surya ^a   Lavie, Carl J ^a   Milani, Richard V ^a   O'Keefe, James ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Erectile dysfunction; Hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; NITRIC ACID DERIVATIVE; PAPAVERINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN DERIVATIVE; SILDENAFIL; TADALAFIL; VARDENAFIL; VASOACTIVE AGENT; CHOLESTEROL;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSLIPIDEMIA; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEG CRAMP; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PENIS ERECTION; PENIS PROSTHESIS; POPULATION RESEARCH; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINITIS; RISK ASSESSMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; SINUSITIS; THORAX PAIN; TREATMENT RESPONSE; UNITED STATES; VASCULAR ENDOTHELIUM; VISUAL IMPAIRMENT; BLOOD; MALE; REVIEW; RISK FACTOR; SMOKING;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; RISK FACTORS; SEXUAL BEHAVIOR; SMOKING;

EID: 84856837283     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.05.2279     Document Type: Article

References (80)

1. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83-90.
2. Ayta IA, McKinlay JB, Krane RJ. The likely world-wide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50-56.
3. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151-157.
4. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000; 30(4):328-338.
5. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(12):1754-1755.
6. Russell ST, Khandheria BK, Nehra A. Erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2004;79(6):782-794.
7. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3(1):28-36.
8. Aboseif SR, Lue TF. Haemodynamics of penile erection. Urol Clin North Am. 1988;15(1):1-7.
9. Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. Mayo Clin Proc. 2006;81(3):385-390.
10. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008;51(21):2040-2044.
11. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000;86(2A):175-181.
12. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113.
13. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23): 2996-3002.
14. Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen study. Int J Impot Res. 2008;20(1):92-99.
15. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium- dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43(2):179-184.
16. Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Clev Clin J Med. 2007;74(suppl 3):S30-S37.
17. De Angelis L, Margella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia. 2001;44(9):1155-1160.
18. Miner MM. Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events. Mayo Clin Proc. 2009;84(2):102-104.
19. Lee JH, Ngengwe R, Jones P, Tang F, O'Keefe JH. Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol. 2008;15(6):800-803.
20. Chew KK, Finn J, Stuckey B, et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med. 2010;7(1 pt 1):192-202.
21. Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol. 2010;55(4):350-356.
22. Batty GD, Li Q, Czernichow S, et al; ADVANCE Collaborative Group. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modifi ed-Release Controlled Evaluation) trial. J Am Coll Cardiol. 2010;56(23):1908-1913.
23. Janiszewski PM, Janssen I, Ross R. Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med. 2009;6(7):1990-1998.
24. Montorsi P, Ravagnani PM, Galli S, et al. The triad of endothelial dysfunction, cardiovascular disease, and erectile dysfunction: clinical implications. Eur Urol. 2009;8:58-66.
25. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163(3):788-791.
26. Davis RM. The Marlboro man needs Viagra. Tob Control.1998; 7(3):227.
27. Goff DC, Gerstein HC, Ginsberg HN, et al; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):4i-20i.
28. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-431.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
30. O'Keefe JH, Abuannadi M, Lavie CJ, et al. Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(2):128-138.
31. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol. 2003;91(2):230-231.
32. Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008;51(21):2045-2050.
33. Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and sexual dysfunction: results from the Olmstead County study of urinary symptoms and health status among men. J Urol. 2007;177(4):1438-1442.
34. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737.
35. Tostes RC, Carneiro FS, Lee JA, et al. Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation. J Sex Med. 2008;5(6):1284-1295.
36. Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol. 1994;140:1003-1008.
37. He J, Reynolds K, Chen J, et al. Cigarette smoking and erectile dysfunction among Chinese men without clinical vascular disease. Am J Epidemiol. 2007;166(7):803-809.
38. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1(8422):181-184.
39. Musicki B, Liu T, Lagoda GA, et al. Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med. 2010;7(9):3023-3032.
40. Cardenas GA, Lavie CJ, Cardenas V, et al. The importance of recognizing and treating low levels of high-density Lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9(4):239-258.
41. deGoma EM, Leeper NJ, Heidenreich PA. Clinical signifi cance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51(1):49-55.
42. Wei M, Macera CA, Davis DR, et al. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140(10):930-937.
43. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol. 2008;51(1):56-58.
44. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol. 2004;172(1):255-258.
45. Dogru MT, Basar MM, Simsek A, et al. Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. Urology. 2008;71(4):703-707.
46. Hall SA, Kupelian V, Rosen RC, et al. Is hyperlipidemia or its treatment associated with erectile dysfunction? Results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2009;6(5):1402-1413.
47. Carvajal A, Macias D, Sáinz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29(2):143-149.
48. Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med. 2010;7(4 pt 1):1547-1556.
49. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6 pt 1):2341-2345.
50. Nehra A. Erectile dysfunction and cardiovascular disease: effi cacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009;84(2):139-148.
51. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253(22):3263-3268.
52. Milbank AJ, Montague DK. Surgical management of erectile dysfunction. Endocrine. 2004;23(2-3):161-165.
53. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(9A):9M-18M.
54. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafi l citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2 suppl 2):28-38.
55. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafi l in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404.
56. Derry FA, Dinsmore WW, Fraser M, et al. Effi cacy and safety of oral sildenafi l (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Neurology. 1998;51(6):1629-1633.
57. Sanchez RA, Vidal J, Jaurequi ML, et al. Effi cacy, safety and predictive factors of therapeutic success with sildenafi l for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord. 2001;39(12):637-643.
58. Derry F, Hultling C, Seftel AD, et al. Effi cacy and safety of sildenafi l citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002;60(2 suppl 2):49-57.
59. Seidman SN, Roose SP, Menza MA, et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafi l citrate. Am J Psychiatry. 2001;158(10):1623-1630.
60. Nurnberg HG, Seidman SN, Gelenberg AJ, et al. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafi l citrate (Viagra) in treated and untreated patients with depression. Urology. 2002;60:58-66.
61. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profi le of sildenafi l citrate. Am J Cardiol. 1999;83(5A):35C-44C.
62. Boolell M, Allen MJ, Ballard SA, et al. Sildenafi l: an orally active type 5 cyclic GMP-specifi c phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47-52.
63. DeBusk RF, Pepine CJ, Glasser DB, et al. Effi cacy and safety of sildenafi l citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004;93(2):147-153.
64. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafi l in patients with erectile dysfunction taking antihypertensive therapy. Sildenafi l Study Group. Am J Hypertens. 2001;14(1):70-73.
65. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafi l citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279-284.
66. Boulton AJ, Selam JL, Sweeney M, et al. Sildenafi l citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44(10):1296-1301.
67. El-Sakka AI. Effi cacy of sildenafi l citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol. 2004;46(4):503-509.
68. Kamel A, Khaouli R, Sabha M, et al. The real-life effi cacy and safety of vardenafi l: an international post-marketing surveillance study of 2824 patients from the Middle East. Clin Drug Investig. 2007;27(5):339-346.
69. Tobing NL, Arsyad KM, Manuputty D, et al. The real-life safety and effi cacy of vardenafi l: an international post-marketing surveillance study from 1171 Indonesian patients. Maj Kedokt Indon. 2006;56(8):468-473.
70. Padma-Nathan H, Porst H, Eardley I, et al. Effi cacy and safety of vardenafi l, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am J Hypertens. 2002;15:A48.
71. Goldstein I, Young JM, Fischer J, et al; Vardenafi l Diabetes Study Group. Vardenafi l, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fi xed-dose study. Diabetes Care. 2003;26(3):777-783.
72. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Effi cacy and safety of fl exible-dose vardenafi l in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006;3(5):883-891.
73. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafi l on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159-2164.
74. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafi l clinical trials. Diabetologia. 2004;47(11):1914-1923.
75. Lewis RW, Sadovsky R, Eardley I, et al. The effi cacy of tadalafi l in clinical populations. J Sex Med. 2005;2(4):517-531.
76. Ebrahim S, May M, Ben Shlomo Y, et al. Sexual intercourse and risk of ischaemic stroke and coronary heart disease: the Caerphilly study. J Epidemiol Community Health. 2002;56(2):99-100.
77. Hall SA, Shackelton R, Rosen RC, Araujo AB. Sexual activity, erectile dysfunction, and incident cardiovascular events. Am J Cardiol. 2010;105(2):192-197.
78. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA. 1996;275(18):1405-1409.
79. Moller J, Ahlborn A, Hulting J, et al. Sexual activity as a trigger of myocardial infarction: a case-crossover analysis in the Stockholm Heart Epidemiology Program (SHEEP). Heart. 2001;86(4):387-390.
80. Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies circulation. Circulation. 2006; 114(17):1863-1872.